Business Wire

IMPRIVATA

Del
Imprivata Survey of 100 European Organisations Confirms Rapid Adoption of Desktop Virtualisation with Single Sign-On

VMworld® (booth E160) -- Within the next 24 months, 74 percent of organisations in Europe adopting virtual desktop infrastructure (VDI) plan to implement single sign-on (SSO), according to new research from Imprivata ®, a leading provider of authentication, access management solutions for the healthcare industry. The Imprivata 2014 Desktop Virtualisation Trends in Europe report also finds that overall adoption of VDI is expected to reach 65 percent within the next 24 months, and in healthcare, 71 percent of organisations expect to be using VDI within the next two years.

“Our virtual desktop infrastructure enables our clinical staff to add roaming desktops and mobility into their work routines, and allowed us to replace about 1,000 desktop PCs with thin clients,” said Justin Beardsmore, Infrastructure Manager, St. George’s Healthcare NHS Trust (London). “By adding SSO and strong authentication though Imprivata OneSign , our providers are collectively saving more than 50 hours every week. The combination of VDI, thin clients, mobile devices and Imprivata OneSign has kick-started St. George’s journey into the mobile health era.”

Key findings from the Imprivata 2014 Desktop Virtualisation Trends in Europe report include:

  • Adoption rates of VDI increased from 41 percent in 2013 to 49 percent in 2014. This trend is expected to continue, with VDI adoption forecasted to reach 65 percent within 24 months. The use of VDI in healthcare is outpacing other industries, with adoption levels expected to reach 71 percent over the next 24 months.
  • Today, 46 percent of organisations that use VDI also use SSO, which is an increase of 18 percent from 2013. This is expected to continue to increase, with 74 percent of organisations indicating they will implement SSO with their VDI environments over the next 24 months.
  • Adoption of zero clients to support VDI is expected to increase 45 percent over the next 24 months, while adoption of thin clients is expected to increase eight percent over that time frame. The use of tablets and smartphones for VDI is also expected to increase sharply, particularly in healthcare.

“The results of the Imprivata 2014 Desktop Virtualisation Trends in Europe report mirror what we continue to hear from our global customers—implementing authentication management solutions to delivering fast, secure access to mission-critical applications and information is integral to unlocking the full potential of desktop virtualisation,” said Clay Ritchey, chief marketing officer at Imprivata. “The combination of these technologies is especially beneficial in healthcare, where providing instant access to clinical applications and patient data at the point of care can significantly improve efficiency while also meeting security and compliance requirements.”

To download the complete 2014 Imprivata Desktop Virtualisation Trends in Europe report, click here .

Methodology

A total of 101 respondents from across the healthcare, financial services, government and other industries in Europe were surveyed to understand their organisation’s adoption rates of desktop virtualisation. Responses were collected from organisations of varying size based on number of employees for non-healthcare respondents and number of beds for healthcare respondents.

About Imprivata

Imprivata (NYSE: IMPR) is a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s single sign-on, authentication management and secure communications solutions enable fast, secure and more efficient access to healthcare information technology systems to address multiple security challenges and improve provider productivity for better focus on patient care. For more information, please visit www.imprivata.com .

This press release may include forward-looking statements regarding anticipated objectives, growth and/or expected product and service developments or enhancements. Such forward-looking statements may be identified by the use of the following words (among others): "believes," "expected," "may," "will," "plan," “growing”, "should", “expected”, "anticipates" or comparable words and their negatives. These forward-looking statements are not guarantees but are subject to risks and uncertainties that could cause actual results to differ materially from the expectations contained in these statements. For a discussion of such risks and uncertainties, see "Risk Factors" in Imprivata’s filings with the Securities and Exchange Commission, including its most recent report on Form 10-Q. Imprivata assumes no obligation to update any forward-looking statements contained in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.

Contact:

PR Contact:
Imprivata
Dan Borgasano, +1-781-430-2812
dborgasano@imprivata.com
or
IR Contact :
Westwicke Partners
Bob East / Asher Dewhurst, 443-213-0503
bob.east@westwicke.com
imprivata@westwicke.com

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release

- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release

With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp

Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release

The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev

7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release

MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye